Unreported use of an herbal supplement resulting in decreased clearance of intravenous busulfan in a patient undergoing auto-SCT

Bone Marrow Transplantation

Volumn 49, Issue 2, 2014, Pages 313-314

  Carter, J ^a   Yeh, R F ^b   Braunschweig, I ^a   Barta, S K ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b SEATTLE CANCER CARE ALLIANCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; BUSULFAN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERB-DRUG INTERACTIONS; HUMANS; MALE; TRANSPLANTATION CONDITIONING;

EID: 84893721235     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.169     Document Type: Letter

References (10)

1. Ernst E, Cassileth BR. The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer 1998; 83: 777-782.
2. Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002; 8: 477-485.
3. Ltd FMD. Flora Flor-Essence Herbal Tea Blend Description (cited 2013, July 22). Available from http://www.florahealth.com/product-conditions-usa.cfm? conditions-id=4&prod-id=211.
4. Leonard BJ, Kennedy DA, Cheng FC, Chang KK, Seely D, Mills E. An in vivo analysis of the herbal compound essiac. Anticancer Res 2006; 26: 3057-3063.
5. Seely D, Kennedy DA, Myers SP, Cheras PA, Lin D, Li R et al. In vitro analysis of the herbal compound Essiac. Anticancer Res 2007; 27: 3875-3882.
6. Lin SC, Chung TC, Lin CC, Ueng TH, Lin YH, Lin SY et al. Hepatoprotective effects of Arctium lappa on carbon tetrachloride-and acetaminophen-induced liver damage. Am J Chinese Med 2000; 28: 163-173.
7. Guo Z, Smith TJ, Wang E, Sadrieh N, Ma Q, Thomas PE et al. Effects of phenethyl isothiocyanate, a carcinogenesis inhibitor, on xenobiotic-metabolizing enzymes and nitrosamine metabolism in rats. Carcinogenesis 1992; 13: 2205-2210.
8. Hassan M, Oberg G, Ehrsson H, Ehrnebo M, Wallin I, Smedmyr B et al. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol 1989; 36: 525-530.
9. Buggia I, Zecca M, Alessandrino EP, Locatelli F, Rosti G, Bosi A et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Anticancer Res 1996; 16: 2083-2088.
10. Freytes CO, Toro JJ, Yeh RF, Stadtmauer EA, Ratanatharathorn V, Akpek G et al. Pharmacokinetics and safety of once-daily intravenous busulfan with bortezomib in patients with relapsed multiple myeloma undergoing a second autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012; 18: S253.